



NATtrol™ Epstein-Barr Virus Strain: B95-8

Catalog Number: NATEBV-0001
Catalog Number: NATEBV-0002
Catalog Number: NATEBV-0003
Catalog Number: NATEBV-0004
Catalog Number: NATEBV-0005
Catalog Number: NATEBV-0006

PRODUCT DESCRIPTION:

NATtrol™ Epstein-Barr Virus (NATEBV-0001, NATEBV-0002, NATEBV-0003, NATEBV-0004, NATEBV-0005, and NATEBV-0006)* is formulated with purified, intact virus particles that have been chemically modified to render them non-infectious and refrigerator stable. Each vial contains 1.0 mL of EBV NATtrol™ at target concentrations listed in Table 1. NATEBV is supplied in a purified protein matrix that mimics the composition of a true clinical specimen.

*Pat.: <http://www.zeptometrix.com/patent-information/>

INTENDED USE:

- NATtrol™ Epstein-Barr Virus is designed to evaluate the performance of nucleic acid tests for determination of the presence of EBV DNA. NATEBV can also be used for validation of clinical assays, development of diagnostic tests and training of laboratory personnel.
- NATEBV contains intact virus and should be run in a manner identical to that used for clinical specimens.

ETIOLOGIC STATUS/BIOHAZARD TESTING:

- NATtrol™ inactivation was carried out on the EBV stock used to formulate this product. The inactivation was verified by the absence of viral growth of a surrogate virus in validated tissue culture based infectivity assays.
- Purified protein matrix used in the manufacture of this product is treated with 0.09% sodium azide. It was manufactured from materials that have been tested and found non-reactive at the donor level for HIV-1/HIV-2 Antibody, HBsAg and HCV Antibody by FDA licensed donor screening test methods. All materials are also tested for HIV-1 and HCV by FDA approved Nucleic Acid Test (NAT) methods. Heat inactivated bovine based source materials used in the manufacture of this product meet applicable USDA requirements for abattoir sourced animals, traceability and country of origin. The materials were collected at USDA licensed establishments or legally imported from countries recognized by the USDA as negligible or controlled for risk for Bovine Spongiform Encephalopathy (BSE) and other exotic disease agents. Donor animals were inspected ante and post mortem at the abattoir as required by the USDA.

PRECAUTIONS:

- Although NATEBV contains inactivated virus, it should be handled as if potentially infectious.
- Use Universal Precautions when handling this product.
- To avoid cross-contamination, use separate pipette tips for all reagents.

RECOMMENDED STORAGE:

- NATtrol™ Epstein-Barr Virus should be stored at 2-8°C.

INSTRUCTIONS FOR USE:

- Extract EBV DNA prior to use in downstream assays.

TABLE 1:

| Catalog Number | Target Concentration (copies/mL)** |
|----------------|------------------------------------|
| NATEBV-0001 | 100 |
| NATEBV-0002 | 500 |
| NATEBV-0003 | 1,000 |
| NATEBV-0004 | 10,000 |
| NATEBV-0005 | 50,000 |
| NATEBV-0006 | 100,000 |

**Conversion factor: 1 copy = 1.62 IU. Based on internal testing of the 1st WHO International Standard for Epstein-Barr Virus for Nucleic acid Amplification Techniques (NIBSC code: 09/260)

**DO NOT USE IN HUMANS. FOR RESEARCH USE ONLY.
NOT FOR USE IN DIAGNOSTIC PROCEDURES.**

These products are intended for research, product development, quality assurance or manufacturing use. These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under section 351 of the Public Health Service Act or for any other product intended for administration to humans.

This product was manufactured in a facility which has a Quality Management System that is ISO 13485 certified.

| | | | |
|-----|-----------------------|--|------------------------|
| REF | Catalog Number | | Temperature Limitation |
| LOT | Lot Number | | Expiration Date |
| RUO | For Research Use Only | | Biological Risk |

ZeptoMetrix Corporation
878 Main Street
Buffalo, NY 14202
800-274-5487
www.zeptometrix.com

PINATEBV-0001
PINATEBV-0002
PINATEBV-0003
PINATEBV-0004
PINATEBV-0005
PINATEBV-0006
Revision: 07
Effective Date: 04/01/2019